Replies to post #210 on Evolus (EOLS)

[DewDiligence]

There isn’t going to be a real accurate trackable “extra strength” usage.

I get that, but the CEO’s comment on the SVB webcast still pertains.

The way the executives danced around the question pertaining to the control arms in the double-dose trial was comical. Unless you're long the stock, of course.